Telix Pharmaceuticals (ASX:TLX) opened a multi-million dollar radiopharmaceutical research, manufacturing, and treatment facility in Melbourne, described as a "first-of-its-kind" Australian purpose-built site, the company said in a statement Thursday.
The company said the facility combines radiochemistry laboratories, clinical product manufacturing, patient dose administration, and imaging under one roof.
The company's shares fell nearly 2% in recent Thursday trade.